Live Updates > Live Update Details
2025-07-31 10:28:52
[Sinopharm's share price hit a four-year high and will receive a $300 million milestone payment from Merck] 1. Sino Biopharm (1177.HK) rose strongly in early trading on Thursday, with the intraday increase expanding to 4.4%, the highest since June 2021. The rise stems from the company's latest announcement showing that its subsidiary has made significant progress in the licensing cooperation with Merck on the anti-cancer drug LM-299/MK-2010, and will receive a $300 million technology transfer milestone payment in the near future. 2. The pharmaceutical company controlled by the Thai Xie family has performed well this year, with its share price soaring 142.8%, far exceeding the Hang Seng Index's 23.7% increase over the same period. It is worth noting that despite Sino Biopharm's strong performance, the Hang Seng Hong Kong Listed Biotech Index (HSHKBIO) fell 0.8% in early trading, indicating that the market's views on the biotech sector are divergent. The progress of this cooperation with the multinational pharmaceutical company Merck has further consolidated Sino Biopharm's market position in the field of innovative drugs.
